Update
$IGC Pharma(IGC.US$ IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
